Krystal Biotech, Inc. (KRYS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Product revenue, net | 96,042 | 88,183 | 83,841 | 70,284 |
| Selling, general and administrative | 35,160 | 32,723 | 28,713 | 27,626 |
| Research and development | 14,410 | 14,255 | 13,511 | 15,583 |
| Litigation settlement | - | - | 12,500 | 12,500 |
| Cost of goods sold | 7,165 | 5,028 | 6,684 | 6,009 |
| Total operating expenses | 56,735 | 52,006 | 61,408 | 61,718 |
| Income from operations | 39,307 | 36,177 | 22,433 | 8,566 |
| Interest and other income, net | 7,468 | 7,420 | 7,336 | - |
| Interest and other income, net | - | - | - | 7,479 |
| Income before income taxes | 46,775 | 43,597 | 29,769 | 16,045 |
| Income tax expense | 8,442 | 7,864 | 2,589 | 477 |
| Net income | 38,333 | 35,733 | 27,180 | 15,568 |
| Foreign currency translation | 925 | - | - | - |
| Unrealized (loss) gain on available-for-sale securities | -158 | 580 | 2,146 | -335 |
| Comprehensive income | 39,100 | 36,313 | 29,326 | 15,233 |
| Basic (in dollars per share) | 1.33 | 1.24 | 0.95 | 0.54 |
| Basic (in shares) | 28,910,000 | 28,815,000 | 28,716,000 | 28,598,000 |
| Diluted (in dollars per share) | 1.29 | 1.2 | 0.91 | 0.53 |
| Diluted (in shares) | 29,749,000 | 29,871,000 | 29,902,000 | 29,637,000 |